Author

T. P. Moreira

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:proteomics· 1

Frequent Co-Authors

C. M. Queiroz-Junior· 2 shared D. G. Souza· 2 shared V. V. Costa· 2 shared A. C. Santos· 1 shared B. R. Barrioni· 1 shared C. D. F. Sousa· 1 shared C. E. Machado Lopes· 1 shared C. S. Bonilha· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. M. Queiroz-Junior

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Essential role of the CCL2-CCR2 axis in Mayaro virus-induced disease

F. M. Santos, V. C. Melo, S. Araujo, C. D. F. Sousa, T. P. Moreira, M. R. Goncalves, A. C. Santos, H. A. Seabra, P. A. C. Costa, B. R. Barrioni, P. B. Souza, M. d. M. Pereira, M. L. Nogueira, D. G. Souza, P. P. Guimaraes, , V. V. Costa

This study shows that the CCL2-CCR2 axis drives inflammation and bone loss in Mayaro virus infection by recruiting macrophages and promoting osteoclastogenesis.

bioRxiv · Jul 21, 2023Cell Biology

Targeting the Annexin A1-FPR2/ALX pathway for host-directed therapy in dengue disease

V. V. Costa, M. A. Sugimoto, J. Hubner, C. S. Bonilha, C. M. Queiroz-Junior, M. H. Goncalves-Pereira, J. Chen, T. Gobbetti, G. O. Libanio Rodrigues, J. L. Bambirra, I. B. Passos, C. E. Machado Lopes, T. P. Moreira, K. Bonjour, R. C. N. Melo, , M. M. Teixeira

This study identifies reduced Annexin A1 levels in dengue patients and mice, showing that AnxA1 agonists reduce disease severity by modulating mast cell degranulation.

bioRxiv · Nov 2, 2021Microbiology